# About Dr PT-141: An Independent PT-141 Research Digest

> About Dr PT-141 — an independent editorial project that publishes cited summaries of the peer-reviewed PT-141 (bremelanotide) literature. Not a clinic, not a vendor.

What this site is, what it is not, and why the "dr" in the name is a position relative to the literature — not a claim about services.

## What Dr PT-141 is

Dr PT-141 is an independent editorial project that publishes summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — the published trials, the FDA prescribing information, and the preclinical record — compiled and cited so a reader can find the source for every figure we report.

## What the "dr" means here

The "dr" in the domain name is editorial framing, not a clinical credential. It signals the register this site occupies relative to the literature: a plain, unembellished clinical-record reading — the label finding and the trial number printed without bedside polish or a storefront gloss. It is not a claim that this site is a doctor, a clinic, or a prescriber, and it is not an offer of consultation, treatment, or prescription. No physician stands behind this page; what stands behind it is the cited record. Any decision about a drug belongs to a qualified clinician who knows the individual.

## How we handle the evidence

We separate what the trials confirmed from what they did not, and we keep community anecdote out of the cited record entirely. Confirmed findings — the RECONNECT coprimary endpoints, the 52-week extension, the fMRI mechanism — are reported with their numbers and sources [3][4][5]. Honest gaps — the modest effect size and the independent re-analyses, the absence of any approval beyond premenopausal HSDD, the lack of oversight on "research chemical" material — are marked as gaps, not smoothed over. And unverified first-hand reports are quarantined in a clearly-labelled "field reports" section, never attributed to a journal. The goal is a document a reader can trust precisely because it does not flatter the compound.

## What this site does not do

This site does not sell, source, price, or supply PT-141 or any other compound, and it does not tell anyone to take it. It does not offer medical advice, diagnosis, or treatment, and it does not host a store or a vendor directory. It summarizes published research and the approved label, and it points to the original sources. If you are weighing anything described here, the right next step is a conversation with a qualified clinician — not this page.

---

PT-141 read as a raw instrument of record — the one approved use, the modest effect, and the nausea-led tolerability cost ruled into the page and cited line by line, with the unverified field reports fenced off behind a dashed border; no clinic behind the grid and nothing here dosed, sourced, or sold.